Sangart, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of oxygen therapeutics. It offers Hemospan, a human hemoglobin-based product that delivers oxygen to tissues at risk of oxygen deprivation. The companys MP4CO, a biopharmaceutical product is used for the treatment of acute painful sickling crises in patients with sickle cell disease
